In light of Schizophrenia Awareness Day, groundbreaking research and a multidisciplinary approach could offer new hope for people living with the condition.
Schizophrenia is a complex mental disorder that affects one in a hundred Australians.
While treatment options exist, roughly 10 per cent of people do not respond to available therapies.
Professor Christos Pantelis at the Melbourne Neuropsychiatry Centre (MNC) of the University of Melbourne said nurses were critical in empowering patients and shaping future care models.
Working alongside nurses, social workers, and occupational therapists, professor Pantelis said compassionate care helped many patients overcome their challenges.
"Nurses have the expertise necessary to manage and care for people living with schizophrenia," he said.
Mental health nurses in psychiatric units provide psychological and social support, assist with behaviour management, as well as helping them transition out of the hospital.
They also assist in reintegration so patients can lead a more normal life in the community.
Professor Pantelis said this often takes considerable time, perseverance and required specialist training for nurses and other clinical staff.
"We firmly believe that we can make a difference in the lives of these young people," he said.
"It may take some time, but we can improve their circumstances."
But he pointed out that a significant proportion of young people living with the disorder were not showing signs of improvement.
He called for innovative research and specialised training to develop tailored interventions for this group.
"For some people, the current drugs we have don't seem to reduce some symptoms, such as apathy, social withdrawal and lack of motivation," professor Pantelis said.
"Nor do they help with problems in cognitive functioning, such as memory and higher level executive impairments.
"We need to find treatments to target these symptoms to improve how people function in their day-to-day lives.
"That's where our research comes in – hopefully, we can have a meaningful impact and make a difference."
Schizophrenia typically affects younger people, with the average onset age being in the early 20s, ranging from the late teens to early thirties.
Professor Pantelis worked closely with professor Patrick McGorry and professor Alison Yung to follow young people at risk of schizophrenia.
They monitored changes in the groups' cognitive functioning and behaviour during brain imaging.
Nearly 40 per cent developed a psychotic illness, including schizophrenia and mood-related psychoses.
In a seminal paper published in Lancet in 2003, professor Pantelis and his team were pioneers in describing the brain changes of people who developed psychosis and schizophrenia for the first time.
This led to a series of studies examining how and why the brains of patients with psychotic disorders, especially schizophrenia, change after the illness begins.
The team examined normal and abnormal trajectories of brain development, revealing dynamic alterations in the frontal and temporal lobes.
These brain regions are crucial for cognitive processes and memory during the initial years of the disorder.
Another recent study published in Molecular Psychiatry, to which professor Pantelis contributed, revealed a link between elevated iron levels in the frontal brain region of individuals with schizophrenia.
This increase was most apparent in the earlier years after illness onset, which is the time when brain changes are most apparent.
This study represented a collaborative national and international effort between researchers from Australia, Israel, the UK and Canada.
Professor Pantelis continued with his team to examine novel brain imaging to examine iron in patients with the disorder.
The results supported and extended the findings from the postmortem study that high iron concentrations found in subcortical structures and associations found between brain changes and iron levels in frontal and temporal brain regions.
"This discovery opens up new avenues for investigating the significance of iron levels in the brain and their potential impact on neural connectivity," professor Pantelis said.
He's now working with researchers from the Monash Institute of Pharmaceutical Sciences to explore new treatments based on cognitive deficits observed in schizophrenia.
Using a neurodevelopmental mouse model, the team maps the normal and abnormal trajectories of brain development.
They hope to find new treatments to help improve cognitive deficits in schizophrenia.
While there's currently no cure for schizophrenia, professor Pantelis said the study's findings offer promising possibilities for early intervention and targeted treatments.
He said that by unravelling the mysteries of the brain, we can address this complex condition for people who don't respond to current treatment options.
"If we continue developing treatments, we hope to make a meaningful impact and improve the circumstances of young people affected by schizophrenia."
